Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Ihab Kamel to Carcinoma, Hepatocellular

This is a "connection" page, showing publications Ihab Kamel has written about Carcinoma, Hepatocellular.

 
Connection Strength
  
 
 
16.803
  
  1. Afyouni S, Zandieh G, Nia IY, Pawlik TM, Kamel IR. State-of-the-art imaging of hepatocellular carcinoma. J Gastrointest Surg. 2024 Oct; 28(10):1717-1725.
    View in: PubMed
    Score: 0.695
  2. Zandieh G, Yazdaninia I, Afyouni S, Shaghaghi M, Borhani A, Mohseni A, Shaghaghi S, Liddell R, Kamel IR. Spectrum of Imaging Findings and Complications After Hepatic Transarterial Chemoembolization for Liver Tumors. J Comput Assist Tomogr. 2024 Sep-Oct 01; 48(5):701-712.
    View in: PubMed
    Score: 0.680
  3. Mohseni A, Baghdadi A, Madani SP, Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, Afyouni S, Zandieh G, Baretti M, Kim AK, Yarchoan M, Kamel IR. Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters. Abdom Radiol (NY). 2024 08; 49(8):2595-2605.
    View in: PubMed
    Score: 0.678
  4. Ansari G, Mirza-Aghazadeh-Attari M, Mohseni A, Madani SP, Shahbazian H, Pawlik TM, Kamel IR. Response Assessment of Primary Liver Tumors to Novel Therapies: an Imaging Perspective. J Gastrointest Surg. 2023 10; 27(10):2245-2259.
    View in: PubMed
    Score: 0.646
  5. Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, Mohseni A, Madani SP, Ansari G, Pawlik TM, Kamel IR. Multimodality imaging of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Surg Oncol. 2023 Sep; 128(4):519-530.
    View in: PubMed
    Score: 0.646
  6. Madani SP, Mirza-Aghazadeh-Attari M, Mohseni A, Pawlik T, Kamel IR. Diffuse infiltrative hepatocellular carcinoma: Multimodality imaging manifestations. J Surg Oncol. 2023 Mar; 127(3):385-393.
    View in: PubMed
    Score: 0.617
  7. Hazhirkarzar B, Shaghaghi M, Baghdadi A, Ghadimi M, Ghasabeh MA, Wu Q, Tang H, Khoshpouri P, Ameli S, Habibabadi RR, Motaghi M, Meyer CF, Kamel IR. Can Posttransarterial Chemoembolization Volumetric Oil Deposition on Computed Tomography Predict Treatment Response on Magnetic Resonance Imaging in Leiomyosarcoma Metastases to the Liver? J Comput Assist Tomogr. 2022 May-Jun 01; 46(3):327-332.
    View in: PubMed
    Score: 0.591
  8. Hazhirkarzar B, Tang H, Ghadimi M, Baghdadi A, Motaghi M, Wu Q, Shaghaghi M, Kamel I. Predicting early necrosis of colorectal liver metastases using volumetric enhancement on baseline MRI and oil deposition on post-cTACE unenhanced CT. Abdom Radiol (NY). 2021 10; 46(10):4610-4618.
    View in: PubMed
    Score: 0.558
  9. Shaghaghi M, AliyariG Hasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Tang H, Khoshpouri P, Wu Q, Pandey A, Pandey P, Baghdadi A, Kamel IR. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. Eur J Radiol. 2020 Dec; 133:109389.
    View in: PubMed
    Score: 0.536
  10. Aliyari Ghasabeh M, Shaghaghi M, Pandey A, Ameli S, Ambale Venkatesh B, Jacob A, Pandey P, Hazhirkarzar B, Luo Y, Rezvani Habibabadi R, Khoshpouri P, Ghadimi M, Kamel IR. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). Eur Radiol. 2021 Mar; 31(3):1630-1641.
    View in: PubMed
    Score: 0.530
  11. Shaghaghi M, Aliyari Ghasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Khoshpouri P, Pandey A, Pandey P, Kamel IR. Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up. Eur Radiol. 2021 Mar; 31(3):1378-1390.
    View in: PubMed
    Score: 0.530
  12. Ameli S, Shaghaghi M, Ghasabeh MA, Pandey P, Hazhirkarzar B, Habibabadi RR, Ghadimi M, Khoshpouri P, Pandey A, Kamel IR. Does the change in volumetric functional MR metrics post-TACE predict histopathologic grading of hepatocellular carcinoma? Eur Radiol. 2020 Dec; 30(12):6709-6720.
    View in: PubMed
    Score: 0.525
  13. Ameli S, Shaghaghi M, Aliyari Ghasabeh M, Pandey P, Hazhirkarzar B, Ghadimi M, Rezvani Habibabadi R, Khoshpouri P, Pandey A, Anders RA, Kamel IR. Role of baseline volumetric functional MRI in predicting histopathologic grade and patients' survival in hepatocellular carcinoma. Eur Radiol. 2020 Jul; 30(7):3748-3758.
    View in: PubMed
    Score: 0.512
  14. Zou X, Luo Y, Li Z, Hu Y, Li H, Tang H, Shen Y, Hu D, Kamel IR. Volumetric Apparent Diffusion Coefficient Histogram Analysis in Differentiating Intrahepatic Mass-Forming Cholangiocarcinoma From Hepatocellular Carcinoma. J Magn Reson Imaging. 2019 04; 49(4):975-983.
    View in: PubMed
    Score: 0.462
  15. Zarghampour M, Fouladi DF, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, Khoshpouri P, Shao N, Pan L, Grimm R, Kamel IR. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors. J Magn Reson Imaging. 2018 10; 48(4):1080-1090.
    View in: PubMed
    Score: 0.448
  16. Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P, Pandey P, Zarghampour M, Fouladi D, Liddell R, Anders RA, Kamel IR. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol. 2018 Jul; 28(7):3032-3040.
    View in: PubMed
    Score: 0.443
  17. Chu LC, Pozzessere C, Corona-Villalobos CP, Castaños S, Rastegar N, Halappa V, Bonekamp S, Emurano E, Kamel IR. Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance. J Comput Assist Tomogr. 2016 Nov/Dec; 40(6):856-862.
    View in: PubMed
    Score: 0.406
  18. Corona-Villalobos CP, Halappa VG, Bonekamp S, Eng J, Reyes D, Cosgrove D, Rastegar N, Pan L, Pawlik TM, Kamel IR. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma. Invest Radiol. 2015 Apr; 50(4):283-9.
    View in: PubMed
    Score: 0.364
  19. Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2015 Feb; 25(2):380-90.
    View in: PubMed
    Score: 0.350
  20. Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. 2014 Mar; 83(3):487-96.
    View in: PubMed
    Score: 0.332
  21. Bonekamp S, Bonekamp D, Geschwind JF, Corona-Villalobos CP, Reyes DK, Pawlik TM, Kamel IR. Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction. J Magn Reson Imaging. 2014 Nov; 40(5):1103-11.
    View in: PubMed
    Score: 0.330
  22. Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology. 2013 Aug; 268(2):420-30.
    View in: PubMed
    Score: 0.318
  23. Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013 Aug; 268(2):431-9.
    View in: PubMed
    Score: 0.318
  24. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011 Sep; 260(3):752-61.
    View in: PubMed
    Score: 0.281
  25. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb; 250(2):466-73.
    View in: PubMed
    Score: 0.237
  26. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007 Jan; 18(1 Pt 1):49-56.
    View in: PubMed
    Score: 0.205
  27. Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar; 17(3):505-12.
    View in: PubMed
    Score: 0.194
  28. Kamel IR, Liapi E, Fishman EK. Multidetector CT of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005 Feb; 19(1):63-89.
    View in: PubMed
    Score: 0.180
  29. Parikh ND, Jones P, Salgia R, Bhan I, Grinspan LT, Jou JH, Zhou K, Jalal P, Roccaro G, Rangnekar AS, Benhammou JN, Pillai A, Mehta N, Wedd J, Yang JD, Kim AK, Duarte-Rojo A, Oloruntoba OO, Tevar A, Au JS, Blain Y, Rao S, Catalano OA, Lewis S, Mendiratta-Lala M, King K, Sachdev L, Lee EW, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski EM, Quirk L, Nathani P, Haydel B, Leven E, Wong N, Albertian R, Chen A, Aloor FZ, Mohamed IB, Elkheshen A, Marvil C, Issac G, Clinton JW, Woo SM, Yum J, Rieger E, Hutchison AL, Turner DA, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper EB, Hao W, Singal AG. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):281-290.e4.
    View in: PubMed
    Score: 0.174
  30. Shahbazian H, Raja K, Sirlin C, Nemzow G, Borhani A, Attari MA, Kamel IR, Chernyak V. Utility of pelvic CT in patients undergoing surveillance for hepatocellular carcinoma: A retrospective multi-institutional study. Abdom Radiol (NY). 2024 11; 49(11):4125-4130.
    View in: PubMed
    Score: 0.172
  31. Shahbazian H, Birnbaum J, Burns PJ, Shabanan SH, Kanmaniraja D, Reinus J, Kamel I, Sirlin CB, Chernyak V. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma. Abdom Radiol (NY). 2023 12; 48(12):3696-3702.
    View in: PubMed
    Score: 0.163
  32. Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, Szarf G, Geschwind JF. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003 Sep; 181(3):708-10.
    View in: PubMed
    Score: 0.163
  33. Alden SL, Lim M, Kao C, Shu D, Singal AG, Noonan A, Griffith P, Baretti M, Ho WJ, Kamel I, Yarchoan M, Hsiehchen D. Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer Res Commun. 2023 07; 3(7):1312-1317.
    View in: PubMed
    Score: 0.162
  34. Kamel IR, Georgiades C, Fishman EK. Incremental value of advanced image processing of multislice computed tomography data in the evaluation of hypervascular liver lesions. J Comput Assist Tomogr. 2003 Jul-Aug; 27(4):652-6.
    View in: PubMed
    Score: 0.161
  35. Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, Pawlik TM. Management of Hepatocellular Carcinoma: A Review. JAMA Surg. 2023 04 01; 158(4):410-420.
    View in: PubMed
    Score: 0.158
  36. Aziz H, Brown ZJ, Panid Madani S, Kamel IR, Pawlik TM. Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review of Diagnosis, Imaging, and Management. J Am Coll Surg. 2023 02 01; 236(2):399-410.
    View in: PubMed
    Score: 0.154
  37. Kamel IR, Bluemke DA. Imaging evaluation of hepatocellular carcinoma. J Vasc Interv Radiol. 2002 Sep; 13(9 Pt 2):S173-84.
    View in: PubMed
    Score: 0.152
  38. Ghadimi M, Birnbaum J, Kamel IR, Sirlin CB, Chernyak V. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria? Eur Radiol. 2022 May; 32(5):3327-3333.
    View in: PubMed
    Score: 0.144
  39. Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer. 2021 09; 2(9):891-903.
    View in: PubMed
    Score: 0.141
  40. Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control. 2021 Jan-Dec; 28:10732748211009945.
    View in: PubMed
    Score: 0.135
  41. Ho WJ, Sharma G, Zhu Q, Stein-O'Brien G, Durham J, Anders R, Popovic A, Mo G, Kamel I, Weiss M, Jaffee E, Fertig EJ, Yarchoan M. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.134
  42. Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol. 2020 May; 17(5S):S70-S80.
    View in: PubMed
    Score: 0.129
  43. Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Hindman NM, Kaur H, McNamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol. 2017 Nov; 14(11S):S391-S405.
    View in: PubMed
    Score: 0.109
  44. Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Hindman NM, Kaur H, McNamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol. 2017 May; 14(5S):S103-S117.
    View in: PubMed
    Score: 0.105
  45. Qu J, Han S, Zhang H, Liu H, Wang Z, Kamel IR, Berthold K, Dominik NM, Zhang S, Dong Y, Jiang L, Liu C, Li H. Improved Detection of Recurrent Hepatocellular Carcinomas in Arterial Phase With CAIPIRINHA-Dixon-TWIST-Volumetric Interpolated Breath-Hold Examination. Invest Radiol. 2016 10; 51(10):602-8.
    View in: PubMed
    Score: 0.101
  46. Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016 Jun; 25(2):74-85.
    View in: PubMed
    Score: 0.097
  47. Samanci C, Sobhani F, Ucbilek E, Rakestraw K, Dagher NN, Kamel IR, Gurakar A. Magnetic Resonance Imaging in Diagnosis and Monitoring of Hepatocellular Carcinoma in Liver Transplantation: A Comprehensive Review. Ann Transplant. 2016 Feb 02; 21:68-76.
    View in: PubMed
    Score: 0.096
  48. Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology. 2015 Nov; 277(2):594-603.
    View in: PubMed
    Score: 0.092
  49. Valero V, Amini N, Spolverato G, Weiss MJ, Hirose K, Dagher NN, Wolfgang CL, Cameron AA, Philosophe B, Kamel IR, Pawlik TM. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg. 2015 Feb; 19(2):272-81.
    View in: PubMed
    Score: 0.089
  50. Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014 Dec; 273(3):746-58.
    View in: PubMed
    Score: 0.087
  51. Mayo SC, Mavros MN, Nathan H, Cosgrove D, Herman JM, Kamel I, Anders RA, Pawlik TM. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg. 2014 Feb; 218(2):196-205.
    View in: PubMed
    Score: 0.082
  52. Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JH, Kamel IR, Pawlik TM. Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma. J Gastrointest Surg. 2013 Oct; 17(10):1774-1783.
    View in: PubMed
    Score: 0.081
  53. Stacy S, Hyder O, Cosgrove D, Herman JM, Kamel I, Geschwind JF, Gurakar A, Anders R, Cameron A, Pawlik TM. Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. J Gastrointest Surg. 2013 Sep; 17(9):1600-8.
    View in: PubMed
    Score: 0.080
  54. Wood LD, Heaphy CM, Daniel HD, Naini BV, Lassman CR, Arroyo MR, Kamel IR, Cosgrove DP, Boitnott JK, Meeker AK, Torbenson MS. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol. 2013 Dec; 26(12):1586-93.
    View in: PubMed
    Score: 0.080
  55. Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013 Mar 01; 119(5):1042-9.
    View in: PubMed
    Score: 0.077
  56. Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology. 2012 Oct; 265(1):115-23.
    View in: PubMed
    Score: 0.076
  57. Peng PD, Hyder O, Bloomston M, Marques H, Corona-Villalobos C, Dixon E, Pulitano C, Hirose K, Schulick RD, Barroso E, Aldrighetti L, Choti M, Shen F, Kamel I, Geschwind JF, Pawlik TM. Sequential intra-arterial therapy and portal vein embolization is feasible and safe in patients with advanced hepatic malignancies. HPB (Oxford). 2012 Aug; 14(8):523-31.
    View in: PubMed
    Score: 0.075
  58. Kneuertz PJ, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman J, Cameron A, Gurakar A, Cosgrove D, Choti MA, Geschwind JF, Kamel IR, Pawlik TM. Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol. 2012 Sep; 19(9):2897-907.
    View in: PubMed
    Score: 0.074
  59. Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012 Apr; 16(4):874-81.
    View in: PubMed
    Score: 0.074
  60. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011 Oct 20; 29(30):3960-7.
    View in: PubMed
    Score: 0.071
  61. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg. 2011 Nov; 15(11):2089-97.
    View in: PubMed
    Score: 0.070
  62. Bonekamp D, Reyes DK, Bonekamp S, Wahlin TA, Geschwind JF, Fishman EK, Kamel IR. Complications of loco-regional therapy in the liver-spectrum of imaging findings by CT and MRI. Emerg Radiol. 2011 Jun; 18(3):249-56.
    View in: PubMed
    Score: 0.068
  63. Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec; 15(6):526-32.
    View in: PubMed
    Score: 0.062
  64. Vossen JA, Buijs M, Liapi E, Eng J, Bluemke DA, Kamel IR. Receiver operating characteristic analysis of diffusion-weighted magnetic resonance imaging in differentiating hepatic hemangioma from other hypervascular liver lesions. J Comput Assist Tomogr. 2008 Sep-Oct; 32(5):750-6.
    View in: PubMed
    Score: 0.058
  65. Dorfman JD, Schulick R, Choti MA, Geschwind JF, Kamel I, Torbenson M, Thuluvath PJ. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol. 2007 Feb 07; 13(5):781-4.
    View in: PubMed
    Score: 0.052
  66. Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006 Sep; 9(3):125-32.
    View in: PubMed
    Score: 0.050
  67. Borhani A, Luu H, Mohseni A, Xu Z, Shaghaghi M, Tolosa C, Attari MMA, Madani SP, Shahbazian H, Khoshpouri P, Afyouni S, Zandieh G, Kamel IR, Kim AK. Screening for exclusion of high-risk bleeding features of esophageal varices in cirrhosis through CT and MRI. Clin Imaging. 2024 Jun; 110:110168.
    View in: PubMed
    Score: 0.043
  68. Hamad A, Aziz H, Kamel IR, Diaz DA, Pawlik TM. Yttrium-90 Radioembolization: Current Indications and Outcomes. J Gastrointest Surg. 2023 03; 27(3):604-614.
    View in: PubMed
    Score: 0.039
  69. Margonis GA, Amini N, Buettner S, Besharati S, Kim Y, Sobhani F, Kamel IR, Pawlik TM. Impact of early postoperative platelet count on volumetric liver gain and perioperative outcomes after major liver resection. Br J Surg. 2016 Jun; 103(7):899-907.
    View in: PubMed
    Score: 0.024
  70. Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg. 2013 Dec; 17(12):2123-32.
    View in: PubMed
    Score: 0.020
  71. Kim B, Woreta T, Chen PH, Limketkai B, Singer A, Dagher N, Cameron A, Lin MT, Kamel I, Gurakar A. Donor-transmitted malignancy in a liver transplant recipient: a case report and review of literature. Dig Dis Sci. 2013 May; 58(5):1185-90.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)